NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib. "We are excited to acquire royalties on vorasidenib, which if approved, would be the first targeted therapy for patients with IDH-mutant glioma," said Pablo Legorreta, founder and Chief Executive Officer of Royalty ...

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024 Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today, Tuesday, ...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET BofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

Royalty Pharma PLC (NASDAQ:RPRX) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Executive Officer Marshall Urist - Executive Vice President & Head, Research & Investments Chris Hite - Vice Chairman & Executive Vice President Terrance Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs ...

For the quarter ended March 2024, Royalty Pharma (RPRX) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this company would post earnings of $1.03 per share when it actually produced earnings of $1.15, delivering a surprise of 11.65%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Exhibit 99.1 ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS • Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million • Net cash provided by operating activities of $665 million • Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million • Commitment to grow dividend by mid-single digit percentage annually NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full yea ...

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma's development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalt ...